Abstract Details

Title Principal Diagnoses Associated with In-Hospital Mortality among Patients with Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 202

Objective

Background BACKGROUND: Mortality deficits in patients with MS relative to non-MS comparators have been identified. However, limited data exist on primary causes of death (CODs) in the hospital setting in these patients.

Design/Methods DESIGN/METHODS: The US-based Premier hospital database was analyzed for inpatients ?18 years who died between January 2007 and December 2011 with principal or secondary ICD-9 diagnosis code 340 for MS. Mutually exclusive comparator groups included deceased inpatients with a 250-250.93 code (DM) or with any other code (GHP). Diagnoses associated with death were identified and classified into 8 categories: MS, cancer, cardiovascular, infection, suicide, accident, pulmonary (non-infectious, non-embolic), and all other. Demographic data, including all patient-refined diagnosis-related groups and comorbid conditions, were collected. All variables were analyzed descriptively.

Results RESULTS: 1,518 deceased patients with MS (mean age [SD]63.4 < 12.4 > years), 140,283 with DM (73.3 < 12.9 > years), and 305,339 in GHP (73.1 < 16.5 >) were identified. Infection was the most common principal diagnosis in MS (43.1% vs 26.3% [DM], 24.0% [GHP]), with the septicemia subcategory more common in the MS cohort (34.5% vs 20.1% [DM], 16.7% [GHP]). Other principal diagnoses in the MS, DM, and GHP cohorts were: MS (3.2%, 0%, 0%), cancer (5.2%, 7.2%, 11.7%), cardiovascular (12.1%, 27.5, 24.3), pulmonary (17.5%, 14.2%, 13.3%), and other (18.9%, 24.7%, 26.8%). Secondary groupings were suicide (0.6%, 0.1%, 0.5%) and accident (19.7%, 21.2%, 22.3%).

Conclusions CONCLUSIONS: Infections associated with death, especially septicemia, occurred more frequently in the MS than DM or GHP cohorts, whereas cardiovascular disease was more common in DM and GHP. Increased awareness of these leading inpatient CODs may improve care for patients with MS.

Authors/Disclosures
Frank R. Ernst, PharmD (Premier Healthcare Alliance) PRESENTER	No disclosure on file
	No disclosure on file
Dirk Pleimes, MD (Bayer Healthcare)	No disclosure on file
Antonio Gallo	Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis.

��ɫ��

��ɫ��